Initial Products Expected to Launch in the First Half of 2007
BOTHELL, Wash., and ELMWOOD PARK, N.J., Dec. 14 /PRNewswire-FirstCall/
-- Helix BioMedix, Inc. (OTC Bulletin Board: HXBM), a developer of
bioactive peptides, and Grant Industries, a privately held developer,
manufacturer and marketer of cosmetic, textile, and performance specialty
chemicals, today announced that they have entered into a marketing
partnership to supply innovative ingredients to the personal care industry
through application of Helix BioMedix's patented peptide technology.
Under license from Helix BioMedix, Grant has developed and validated
peptide-based and peptide-enhanced ingredient blends for skin care
applications targeting improvement in the appearance of acne-prone skin or
reduction of visible signs of aging such as lines, wrinkles and loss of
firmness and elasticity. The license agreement is the culmination of a
collaborative venture to bring advanced skin care science to more consumers
by leveraging the respective strengths of each organization.
Paul Granatell, Executive Director of Grant Industries, commented, "We
have high expectations that our partnership with Helix BioMedix will
provide our customer companies with a significant edge in the highly
competitive cosmeceutical skin care market. We've already invested
substantial resources targeting the development and validation of new
cosmetic ingredients based on Helix BioMedix's peptides in anticipation of
the completion of this license negotiation."
R. Stephen Beatty, President and Chief Executive Officer of Helix
BioMedix, added, "We are delighted with the cosmetics industry know-how
that Grant Industries has brought to this partnership. As a
technology-focused company, Helix BioMedix's expertise is in the
identification and validation of new peptides for cosmetic application.
However, in the cosmetics and personal care arena, a critical component of
success is the ultimate ability to apply the technology to build a final
product that is efficacious, safe and cosmetically elegant. Grant's
expertise in technology application is the perfect complement to Helix's
expertise in technology development."
Initial products developed through the partnership on behalf of
cosmetic and personal care industry manufacturers and marketers are
expected to launch in the first half of 2007.
About Grant Industries
Grant Industries is a privately held company, located in Elmwood Park,
NJ, involved in the research, development, manufacturing, and marketing of
cosmetic, textile, and performance specialty chemicals. The company's
involvement in the textile industry dates back 60 years and four
generations. Grant offers the cosmetic industry a diversified product line
of Gransil silicone elastomer gels and powders, specialty materials and
formulated products. The company maintains manufacturing and warehousing in
Elmwood Park, NJ, Mexico, Dominican Republic, England, Korea, Japan, China,
South Africa and the European Union. More information about the company can
be found on the company's website at http://www.grantinc.com.
About Helix BioMedix
Helix BioMedix, Inc. is a biopharmaceutical company that has a
portfolio of issued patents that covers six distinct classes of peptides,
covering over 100,000 unique peptide sequences. The company's mission is to
become the industry leader in developing and commercializing small proteins
known as bioactive peptides. The antimicrobial and wound healing properties
of these peptides qualify them for inclusion in a wide range of both
pharmaceutical and consumer products. The company is currently focused on
the development of selected peptides as topical anti-infectives and in
wound healing. Non- pharmaceutical applications being pursued by Helix
BioMedix include adjuvants for cosmetics/cosmeceuticals, personal care,
plant health, animal health and wide-spectrum biocides. More information
about the company and its proprietary peptides can be found on the
company's website at http://www.helixbiomedix.com.
Important Notice
This press release contains forward-looking statements (statements
which are not historical facts) within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements
include statements regarding activities, events or developments that Helix
BioMedix, Inc. (the "company" or "our") expects, believes or anticipates
may occur in the future, including statements related to our potential
growth, product development and commercialization and revenue. A number of
factors could cause actual results to differ from those indicated in the
forward-looking statements, including the company's ability to successfully
raise additional capital, enter into revenue generating license agreements,
continue its research and development efforts, including pre-clinical and
clinical studies, and general economic conditions. Additional assumptions,
risks and uncertainties are described in detail in our reports and other
filings with the Securities and Exchange Commission. Such filings are
available on our website or at http://www.sec.gov. Readers are cautioned that such
forward-looking statements are not guarantees of future performance and
that actual results or developments may differ materially from those set
forth in the forward-looking statements. The company undertakes no
obligation to publicly update or revise forward-looking statements to
reflect subsequent events or circumstances.
Contact: Investor Relations:
Helix BioMedix, Inc. Cameron Associates
David H. Kirske, Alison Ziegler, 212-554-5469
425-402-8400 alison@cameronassoc.com
dkirske@helixbiomedix.com
or:
Grant Industries, Inc.
Paul Granatell,
201-791-8700
pgranatell@grantinc.com
SOURCE Helix BioMedix, Inc.
 back to top
Related links:
http://www.helixbiomedix.com
http://www.grantinc.com
CONTACT:
David H. Kirske of Helix BioMedix, Inc.,
+1-425-402-8400, dkirske@helixbiomedix.com; or Paul Granatell of
Grant Industries, Inc., +1-201-791-8700, pgranatell@grantinc.com;
or Investor Relations, Alison Ziegler of Cameron Associates,
+1-212-554-5469, alison@cameronassoc.com
|
